Literature DB >> 2549797

Giant axonal neuropathy. A review.

R A Ouvrier1.   

Abstract

First reported in 1972 by Berg & colleagues, giant axonal neuropathy is a generalized disorder of cytoplasmic intermediate filaments affecting the nervous system particularly. The condition was originally thought to be a disorder of the peripheral nervous system, but clinical and pathological evidence has now accumulated which indicates that the brain and spinal cord are progressively involved. Over 20 cases have been reported to date. All cases reported have developed clumsiness and progressive weakness with hyporeflexia in the first seven years of life. Later dysarthria, cerebellar signs and pyramidal tract disturbances appear. Mental retardation, dementia and seizures are sometimes seen. Tightly curled hair is characteristic of, but not invariably present in, the condition. This disorder, as well as a similar condition affecting dogs, appears to be transmitted by autosomal recessive inheritance. No treatment is effective. Most cases are wheelchair bound or dead by the end of the second decade.

Entities:  

Mesh:

Year:  1989        PMID: 2549797     DOI: 10.1016/s0387-7604(89)80038-5

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  9 in total

1.  Intracisternal inclusions in Schwann cells of the sural nerve.

Authors:  H Kusaka; T Imai
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

2.  Giant axonal neuropathy: clinical and genetic study in six cases.

Authors:  E Demir; P Bomont; S Erdem; L Cavalier; M Demirci; G Kose; S Muftuoglu; A N Cakar; E Tan; S Aysun; M Topcu; P Guicheney; M Koenig; H Topaloglu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

3.  Genome-wide screen identifies drug-induced regulation of the gene giant axonal neuropathy (Gan) in a mouse model of antiretroviral-induced painful peripheral neuropathy.

Authors:  Susan G Dorsey; Carmen C Leitch; Cynthia L Renn; Sherrie Lessans; Barbara A Smith; Xiao M Wang; Raymond A Dionne
Journal:  Biol Res Nurs       Date:  2009-07       Impact factor: 2.522

Review 4.  Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease?

Authors:  Marcel Maier; Philipp Berger; Ueli Suter
Journal:  J Anat       Date:  2002-04       Impact factor: 2.610

5.  Sensory-motor deficits and neurofilament disorganization in gigaxonin-null mice.

Authors:  Thibault Ganay; Alexia Boizot; Renaud Burrer; Jean Paul Chauvin; Pascale Bomont
Journal:  Mol Neurodegener       Date:  2011-04-12       Impact factor: 14.195

6.  Giant Axonal Neuropathy: Clinical, Radiological, and Genetic Features.

Authors:  Meenal Garg; Shilpa D Kulkarni; Anaita Udwadia Hegde; Margi Desai; Rafat J Sayed
Journal:  Ann Indian Acad Neurol       Date:  2018 Oct-Dec       Impact factor: 1.383

Review 7.  Ethical challenges for a new generation of early-phase pediatric gene therapy trials.

Authors:  Alexander A Iyer; Dimah Saade; Diana Bharucha-Goebel; A Reghan Foley; Gilberto 'Mike' Averion; Eduardo Paredes; Steven Gray; Carsten G Bönnemann; Christine Grady; Saskia Hendriks; Annette Rid
Journal:  Genet Med       Date:  2021-07-07       Impact factor: 8.822

8.  Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin.

Authors:  Jianqing Ding; Jia-Jia Liu; Anthony S Kowal; Timothy Nardine; Priyanka Bhattacharya; Arthur Lee; Yanmin Yang
Journal:  J Cell Biol       Date:  2002-07-29       Impact factor: 10.539

9.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy.

Authors:  Rachel M Bailey; Diane Armao; Sahana Nagabhushan Kalburgi; Steven J Gray
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.